Lanreotide as Treatment of Polycystic Livers

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To assess the efficacy of lanreotide in controling total liver volume in patients with polycystic livers this study will be performed. A minimum of 38 patients will be recruited and randomized (1:1) to receive either verum or placebo. Lanreotide is already used in other disease states and found to be safe and non-toxic.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Radboud University
• Collaborator: Ipsen
• Treatments: Angiopeptin; Lanreotide; Somatostatin

Criteria

Inclusion Criteria:

• 18 yrs-of age

• Multiple cysts > 20

• Cooperating patient

• Is willing and able to comply with the study drug regimen and all other study requirements

• Willingness to give written informed consent

Exclusion Criteria:

• Use of oral anticonceptives or estrogen suppletion

• Females who are pregnant or breast-feeding

• History or other evidence of chronic pulmonary disease associated with functional limitation

• History of severe cardiac disease

• History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study

• Symptomatic gallstones

• Renal failure requiring hemodialysis